As public furor mounts, Sanofi makes deep cuts to US insulin prices in savings program
Insulin, the life-saving hormone for the millions of diabetics in the United States, is being stockpiled, rationed and foregone to disastrous consequences, as patients struggle to afford the soaring costs of the drug. Provoked and prodded with bipartisan furor, stakeholders in the insulin supply chain are taking steps to ostensibly improve access. On Wednesday, Sanofi — one of three big global insulin makers — pledged that come June, patients will be able to pay $99 to access up to 10 boxes of pens and/or 10 mL vials per month, a far cry from the current iteration of its savings program, in which the French drugmaker charges $99 for one 10mL vial or $149 per box of pens.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
